UR241-2

**UR241-2** is an investigational small molecule **inhibitor** that targets interleukin-1 receptor-associated kinase 1 and 4 (**IRAK1/4**), key mediators in the IL-1/Toll-Like Receptor (TLR) signaling pathway. The drug displays a high degree of selectivity for these kinases and robustly suppresses downstream activities including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation[4][5][7]. UR241-2 disrupts leukemia stem cell clonogenicity and engraftment in cellular and animal models of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and potentially other hematologic cancers, with minimal impact on normal hematopoietic stem/progenitor cells[1][4][5][7]. It is developed to target resistant and relapsed AML through inhibition of IL-1/IRAK1/4 signaling, aiming to eradicate the leukemia stem cell population and improve clinical outcomes.

Other names

UR241-2UR-241-2UR 241-2